Why this poison is interesting

Clonidine closes Band B because it is the poisoning most likely to be mistaken for a different one. The UK label describes the syndrome as arising from a generalised sympathetic depression and lists pupillary constriction, somnolence including coma, hypotension, bradycardia, hypothermia, respiratory depression including apnoea.¹ Set that beside the opioid page and the overlap is close to complete: pinpoint pupils, a depressed conscious level and inadequate breathing are the findings that define an opioid overdose at the bedside.

The label then does something rather startling. Under treatment it states: naloxone may be a useful adjunct for the management of clonidine-induced respiratory depression.¹ A summary of product characteristics for an antihypertensive is recommending the opioid antagonist. The usual explanation — that alpha-2 and mu receptors overlap functionally, so an opioid antagonist reaches the clonidine syndrome — is repeated everywhere, and the best available review says it could not fully account for these symptoms.²

The third reason is a matter of scale. Clonidine is dosed in micrograms: the tablet used as the reference label here contains 25 micrograms.¹ Drugs dosed in micrograms have small absolute margins, and the same receptors are reached by an entirely separate group of products — the imidazoline nasal decongestants and eye drops — which are sold without prescription, stored in bathrooms, and packaged in volumes a small child can swallow.²

A poison is a drug whose kinetics have escaped its pharmacology.

The toxic principle

Clonidine is an agonist, not an antagonist, and that is the first thing to hold onto. It stimulates alpha-2 adrenoceptors, which are predominantly presynaptic and inhibitory. Stimulating an inhibitory autoreceptor in the brainstem vasomotor centres reduces noradrenaline release from the neurons that maintain sympathetic outflow. The drug produces sympathetic blockade by switching something on, not off.

Respiratory depression is the exception, and it is the finding that makes the opioid comparison more than superficial. Central alpha-2 stimulation reducing arousal will reduce respiratory drive, but the label lists apnoea specifically¹ — and an apnoeic patient is doing something more than being sleepy. This is the point at which the standard mechanistic account starts to strain.

The opioid-overlap explanation is taught more confidently than it is known

The conventional account is that alpha-2 and mu-opioid receptors are functionally coupled — both Gi-coupled, both on overlapping neuronal populations, both hyperpolarising via inwardly rectifying potassium channels — so that clonidine reproduces the opioid syndrome and naloxone partially reverses it. Lowry and Brown's review of 173 papers describes exactly this assumption and then states that the effects at the alpha-2 receptor could not fully account for these symptoms, and that clonidine acts in the central nervous system through selective imidazoline receptors as well.² Imidazoline-1 receptors are involved in the hypotensive activity of clonidine and related compounds, and appear to sit upstream of the alpha-2 receptor, working in tandem with it.² Traditional teaching

The review also lists further mechanisms that have been implicated — N-type calcium channels, G-protein inwardly rectifying potassium channels, adenosine receptors, phosphatidylcholine-specific phospholipase C and nicotinic receptors.² The honest summary is that clonidine is a promiscuous central drug whose clinical syndrome is well described and whose receptor accounting is incomplete.

Toxicokinetics

Clonidine — unremarkable kinetics attached to a very potent molecule
Parameter	Therapeutic	In overdose	Why it changes
Absorption	Highly absorbed with only a minor first-pass effect; peak plasma concentrations at 1–3 h¹	Similar; onset of the syndrome is correspondingly early	Unlike the modified-release calcium-channel blockers, there is no pharmaceutical delay to catch anyone out. Clonidine declares itself within a few hours.
Dose proportionality	Dose-proportional across 75–300 micrograms, though dose linearity has not been fully demonstrated over that range¹	Untested and unknown above it	The label is candid that linearity is not established even within the therapeutic range. Extrapolating a concentration–effect relationship to overdose doses has no support.
Protein binding	30–40%¹	Unchanged	Intermediate binding. It is not the reason clonidine is not dialysed — nobody has assessed the question, and EXTRIP has never addressed the drug.⁴
Distribution	Rapidly and extensively distributed into tissues; crosses the blood–brain barrier and the placenta¹	Unchanged	CNS penetration is the entire pharmacology — a peripherally restricted alpha-2 agonist would be a very different drug. It is also why the syndrome is dominated by central rather than cardiac findings.
Metabolism	Modest. The main metabolite, p-hydroxy-clonidine, is pharmacologically inactive¹	Unchanged	No bioactivation, and no active metabolite to prolong the effect. Metabolism here genuinely terminates the action, which is not true of the benzodiazepines or of verapamil.
Elimination	About 70% in the urine, of which 40–60% of the dose is unchanged parent drug; approximately 20% faecal¹	Unchanged route; slower with renal impairment	A substantially renally cleared drug in a patient who may be hypotensive and hypothermic. The label already advises extreme care in renal failure at therapeutic doses.¹
Half-life	5 to 25.5 hours — a fivefold range across individuals¹	Prolonged to 41 hours in severe renal impairment¹	The width of that range is itself the clinical point. A duration of effect that varies fivefold between people, before any renal impairment is added, makes a single fixed observation period difficult to justify from kinetics alone.
Concentration–effect	Antihypertensive effect between about 0.2 and 2.0 ng/mL in normal renal function¹	Above 2.0 ng/mL the hypotensive effect is attenuated or decreases¹	A label explicitly describing a reversal of the dose–response is unusual and is the mechanistic basis of the biphasic blood pressure. It is also a warning against reasoning about severity from blood pressure alone.
Dialysability	—	Unassessed. EXTRIP has published no recommendation covering clonidine or the alpha-2 agonists⁴	The workgroup's published index is the authoritative record of what has been reviewed. An absence of a recommendation is not a recommendation against — it means the question has not been put. Given a moderate volume of distribution and 30–40% protein binding, the theoretical case is not absurd; it simply has never been made.

Metabolism and the metabolites

There is little to say, and that is worth saying. Clonidine undergoes only a minor first-pass effect, 40–60% of the dose is excreted unchanged in the urine, and the main metabolite, p-hydroxy-clonidine, is pharmacologically inactive.¹

Clonidine — a drug that leaves mostly as itself

ClonidineAlready the active and toxic species. Minor first-pass effect only¹
Central alpha-2 and imidazoline-1 receptors, brainstemWhere the syndrome is generated. I-1 receptors appear to sit upstream of alpha-2 and act in tandem²
Renal excretionUrine — 40–60% of dose as unchanged drugAbout 70% of the dose leaves by this route¹
Hepatic hydroxylationp-Hydroxy-clonidinePharmacologically inactive¹ — a genuine detoxification

The class extends well beyond clonidine itself, and the extensions matter because they are encountered in different settings. Moxonidine is a more selective imidazoline-1 agonist used as an antihypertensive. Dexmedetomidine is a highly selective alpha-2 agonist used for sedation in critical care — the same pharmacology deployed deliberately, which is why its therapeutic effect profile reads like a controlled version of this poisoning. Tizanidine is used as an antispasmodic. And the imidazoline decongestants and eye drops — oxymetazoline, xylometazoline, tetrahydrozoline, brimonidine — reach the same receptors from a bottle bought without a prescription.²

Elimination and accumulation

Two features of the elimination shape clinical behaviour: the fivefold inter-individual spread in half-life, and the drug's renal dependence in a patient the poisoning may render hypotensive.

The mirror image of this poisoning deserves its place here, because it is the commoner clinical problem. Abrupt withdrawal of established clonidine therapy produces rebound hypertension: chronic alpha-2 stimulation is associated with adaptive upregulation of the sympathetic system it has been suppressing, and removing the suppression suddenly leaves that system unopposed. A patient admitted for another reason whose clonidine is not prescribed on the ward can become hypertensive and agitated for reasons that have nothing to do with poisoning — the opposite syndrome, from the same receptor, produced by stopping rather than starting.

Target organs — and why those

Brainstem vasomotor centres

TargetPresynaptic alpha-2 adrenoceptors, and imidazoline-1 receptors, in the medulla

Why hereThis is the origin of essentially the whole syndrome. Stimulating inhibitory autoreceptors on the neurons that generate sympathetic outflow reduces that outflow, and the cardiovascular findings follow directly. Lowry and Brown place I-1 receptors upstream of the alpha-2 receptor, working in tandem for the effect on blood pressure² — so this card describes two receptor systems, not one. Inferred

At the bedsideHypotension and bradycardia, described on the label as a generalised sympathetic depression.¹ Atropine is suggested for symptomatic bradycardia, and fluids or inotropic sympathomimetics for hypotension.¹

Locus coeruleus and ascending arousal system

TargetAlpha-2 autoreceptors on noradrenergic neurons

Why hereNoradrenergic projections from the locus coeruleus are a principal maintainer of wakefulness. An alpha-2 agonist suppresses their firing — which is precisely why dexmedetomidine is used as a sedative in critical care. The sedation is not a side effect of the antihypertensive action; both are the same action in different projections. Established

At the bedsideSomnolence progressing to coma.¹ The conscious level can be profound while the patient remains rousable and haemodynamically stable, which is part of why the picture is confusing.

Respiratory centres

TargetNot fully characterised

Why hereThe least well explained finding, and the most dangerous. Reduced arousal alone would predict hypoventilation; the label lists respiratory depression including apnoea.¹ The conventional explanation invokes functional overlap with mu-opioid receptors on the same brainstem populations, and that is the account Lowry and Brown report as insufficient to fully account for the clonidine syndrome they examined — their own worked examples are bradycardia, miosis and hypotension rather than respiratory depression, so the contest applies to the overlap account in general rather than to this finding specifically.² Seger's review concluded that reported treatment approaches vary widely, demonstrating the lack of science on which current treatment is based.³ Traditional teaching

At the bedsideApnoea, and the label's suggestion of naloxone as an adjunct for it.¹ This is the finding that most often prompts the incorrect diagnosis of opioid overdose — and the one for which the borrowed treatment is offered.

Pupil

TargetSympathetic innervation of the dilator pupillae, withdrawn

Why hereThe pupil's diameter is a balance between sympathetic dilatation and parasympathetic constriction. Remove the sympathetic contribution centrally and parasympathetic tone is unopposed. The miosis of clonidine poisoning and the miosis of opioid poisoning are produced by different routes to the same imbalance — opioids act on the Edinger–Westphal nucleus to increase parasympathetic outflow, clonidine by removing sympathetic outflow. Inferred

At the bedsidePupillary constriction, listed first among the label's manifestations of intoxication.¹ Indistinguishable at the bedside from opioid miosis.

Vascular smooth muscle

TargetPostsynaptic alpha-2 adrenoceptors — the peripheral, opposing action

Why hereThe one target that pulls the other way. Stimulation here causes vasoconstriction, which at overdose concentrations competes with the central sympatholysis. The label's statement that the hypotensive effect is attenuated or decreases with plasma concentrations above 2.0 ng/mL¹ is this competition made quantitative. Inferred

At the bedsideVery occasionally hypertension¹, typically early. The label notes severe persistent hypertension may require an alpha-adrenoceptor blocking drug¹ — treating the peripheral action while the central one is still developing.

Thermoregulation

TargetCentral sympathetic control of vasoconstriction and shivering

Why hereBoth mechanisms for defending core temperature are sympathetically driven, and both are suppressed. Hypothermia is therefore a predictable consequence of the same lesion rather than an environmental accident — though environmental exposure in an unconscious patient compounds it. Inferred

At the bedsideHypothermia, listed on the label.¹ It matters because it slows drug elimination further and because it is an additional cause of the bradycardia already present.

Timeline of effects

Clonidine overdose — early, and then prolonged for an unpredictable length of time

Time

What you seeWhat is happening

0–1 hAbsorption
What you seeDrowsiness may already be developing. Children may deteriorate quickly.
What is happeningHighly absorbed with only a minor first-pass effect¹; the drug crosses the blood–brain barrier readily.
0–2 hThe hypertensive phase, if it happens
What you seeBlood pressure may be high, which misdirects the diagnosis.¹
What is happeningPeripheral postsynaptic alpha-2 vasoconstriction, before central sympatholysis has fully developed. The label's hypotensive effect is attenuated or decreases above 2.0 ng/mL¹ describes the same competition.
1–3 hPeak concentration, and the full syndrome
What you seeMiosis, somnolence to coma, bradycardia, hypotension, hypothermia, respiratory depression and apnoea.¹ At this point the patient looks like an opioid overdose.
What is happeningPeak plasma concentrations at 1–3 h.¹ Central sympathetic outflow suppressed; arousal, vasomotor tone, cardiac drive, thermoregulation and pupillary dilatation all withdrawn together.
3–24 h+The plateau of unpredictable length
What you seeSustained depression of consciousness and breathing. How long is genuinely not predictable in the individual patient.
What is happeningHalf-life anywhere from 5 to 25.5 hours¹ — a fivefold spread — with no active metabolite contributing. The gap drawn here is uncertainty, not latency: the effect is fully present and its endpoint cannot be calculated.
Up to 41 hRenal impairment
What you seeProlonged further.
What is happeningThe label gives a terminal half-life of up to 41 hours in severe renal impairment¹, with 40–60% of the dose normally excreted unchanged in urine.¹
On withdrawalThe opposite syndrome
What you seeRebound hypertension and agitation in a patient whose established clonidine is stopped abruptly.
What is happeningChronic suppression of sympathetic outflow removed suddenly. Not a poisoning at all — the mirror image of one, and the commoner clinical event.

What the mechanism predicts at the bedside

Miosis, coma and apnoea do not establish an opioid ingestion. Clonidine produces all three by a different route, and its label lists them explicitly.¹
A hypertensive patient may still have taken clonidine — early hypertension is characteristic rather than exclusionary, and the label records that the hypotensive effect attenuates above 2.0 ng/mL.¹
A partial or absent response to naloxone does not exclude clonidine, and a partial response does not confirm an opioid. The label offers naloxone as an adjunct¹; the evidence behind that is discussed below and is weak.
Check the temperature. Hypothermia is part of the syndrome¹ and is not usually a feature of uncomplicated opioid poisoning — one of the few findings that separates them.
Bradycardia is more prominent than in opioid poisoning, because sympathetic withdrawal acts directly on the heart rather than only through hypoxia.
Ask about the household's other bottles when a child is involved. Nasal decongestants and eye drops reach the same receptor system², and the volumes involved are small.
A fivefold range in half-life means kinetics cannot set the observation period¹, and renal impairment extends it to 41 hours.
Do not stop a patient's established clonidine abruptly — the rebound is a genuine and separate problem.
Dialysis has never been assessed.⁴ That is an absence of evidence, not evidence of absence, and it is not a reason to request it.

The antidote, from the poison's side

The label is explicit that there is no specific antidote for clonidine overdose, and then, two sentences later, suggests naloxone.¹ That tension is the honest state of the field.

What naloxone is doing here, and how confident anyone can be

The proposed rationale is that alpha-2 and mu-opioid receptors are functionally coupled — both Gi-coupled, hyperpolarising the same brainstem neurons — so an opioid antagonist can reach part of the clonidine syndrome. Lowry and Brown, reviewing 173 papers, report exactly this assumption and conclude that the effects at the alpha-2 receptor could not fully account for these symptoms, identifying selective imidazoline receptors as an additional site of action, with I-1 receptors involved in the hypotensive activity and apparently upstream of alpha-2.² Seger's review of clonidine toxicity found that reported treatment approaches vary widely, demonstrating the lack of science on which current treatment is based, and called for multicentre trials to evaluate treatment options.³ Traditional teaching

The badge above marks the mechanistic claim, not the practice. Naloxone appears on a UK label as an adjunct for clonidine-induced respiratory depression¹, and that is a licensing position this page has no business contradicting. What is downgraded is the confident teaching that alpha-2/mu overlap is the reason it works — a claim repeated far more often than the evidence supports, contested by the best available receptor review², and sitting on a treatment literature that its own reviewer described as lacking science.³ This is exactly the shape of claim this library badges: universally taught, plausible, and not demonstrated.

Naloxone: Named on the label: naloxone may be a useful adjunct for the management of clonidine-induced respiratory depression.¹ Mechanism contested²; treatment literature weak.³
Atropine: For symptomatic bradycardia.¹ It opposes the unopposed vagal tone rather than the alpha-2 stimulation, so it treats a consequence rather than the cause.
Fluids and inotropic sympathomimetics: For hypotension.¹ They supply the adrenergic drive that central sympatholysis has withdrawn — acting downstream of the lesion, which is why the response is usually adequate.
Alpha-adrenoceptor blockade: For severe persistent hypertension.¹ Notable as the only treatment on the list aimed at the drug's own peripheral action rather than at its central one.
Activated charcoal: Should be performed where appropriate.¹ Clonidine is a small organic molecule and is adsorbed, unlike lithium.
Extracorporeal removal: Never assessed. EXTRIP has published no recommendation covering clonidine or the alpha-2 agonists.⁴

Critical appraisal

The opioid-overlap mechanism carries a traditional-teaching badge on the strength of a citation for the doubt, not an absence of one for the claim. Lowry and Brown reviewed 173 papers and reported that alpha-2 effects could not fully account for these symptoms, identifying imidazoline receptors as an additional and possibly upstream site.² Seger separately found the treatment literature to lack science³ — which contests the confidence with which clonidine poisoning is managed rather than the receptor account itself. Lowry alone carries the mechanistic contest, and it is sufficient.
This does not mean naloxone should not be given. It is on the UK label as an adjunct¹, the decision belongs to TOXBASE and NPIS, and a badge on a mechanism is not a recommendation against a licensed treatment. The two things are frequently confused and are worth keeping apart.
The imidazoline-receptor account is itself incomplete. Lowry and Brown list several further implicated mechanisms — N-type calcium channels, GIRK channels, adenosine receptors, phospholipase C and nicotinic receptors². Replacing one confident single-receptor story with another would repeat the error.
The biphasic blood-pressure explanation is inference. The label states the two observations — occasional hypertension in overdose, and attenuation of the hypotensive effect above 2.0 ng/mL¹. Attributing this to peripheral postsynaptic alpha-2 vasoconstriction competing with central sympatholysis is the standard reading and is not demonstrated on the label itself.
The thermoregulatory and pupillary mechanisms are reconstructions from autonomic physiology, not findings from poisoned humans. They are marked as inference for that reason.
No paediatric threshold appears on this page. Figures of the 'one tablet can harm a toddler' kind circulate widely; this page prints none, because a threshold that cannot be traced to a verifiable source has no place here and because paediatric risk assessment is precisely what NPIS exists for.
EXTRIP's silence is an absence, not a verdict.⁴ Clonidine's protein binding of 30–40%¹ does not obviously rule out removal; the question has simply never been assessed, and this page should not be read as having answered it.
Rebound hypertension on withdrawal is well recognised clinically; the adaptive-upregulation explanation offered here is the conventional account and is not sourced to a study on this page.

References

1
Clonidine 25 microgram Tablets BP — Summary of Product Characteristics. electronic medicines compendium, product 6538. Sections 4.2, 4.9 (Overdose) and 5.2 (Pharmacokinetic properties). medicines.org.uk/emc/product/6538
2
Lowry JA, Brown JT. Significance of the imidazoline receptors in toxicology. Clinical Toxicology 2014 Jun;52(5):454–69. PMID 24666288. (Review of 173 included papers; states that alpha-2 receptor effects could not fully account for the clonidine syndrome, and describes the imidazoline-1 receptor as upstream of alpha-2 in its hypotensive action.)
3
Seger DL. Clonidine toxicity revisited. Journal of Toxicology — Clinical Toxicology 2002;40(2):145–55. PMID 12126186. (Concludes that reported treatment approaches vary widely, demonstrating the lack of science on which current treatment is based.)
4
EXTRIP Workgroup — published recommendations index. Extracorporeal Treatments in Poisoning Workgroup. Cited for the absence of any recommendation covering clonidine or the alpha-2 agonists. extrip-workgroup.org/recommendations

Clonidine and central α₂ agonists

At a glance